<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581513</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1301104</org_study_id>
    <nct_id>NCT03581513</nct_id>
  </id_info>
  <brief_title>Deferred or Immediate Stent Implantation Based on Microvascular Function in STEMI</brief_title>
  <acronym>SALVAGE</acronym>
  <official_title>Deferred Versus Immediate Stent Implantation for Preventing Microvascular Dysfunction and Improving Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction (SALVAGE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiamusi City Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mudanjiang cardiovascular hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shuangyanshan Mining Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Jiamusi University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daqing Longnan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Timely percutaneous coronary intervention (PCI) with stenting implantation is the current&#xD;
      standard treatment for patients with ST-segment elevation myocardial infarction (STEMI).&#xD;
      However, stenting in thrombus-laden artery is associated with higher risk of embolization and&#xD;
      no-or slow-reflow, leading to larger infarct size and poor prognosis. The SALVAGE study is a&#xD;
      prospective, multicenter, randomized, controlled study aimed to optimize the therapeutic&#xD;
      strategies (deferred vs. immediate stenting) based on microcirculation function assessed by&#xD;
      IMR to protect microvascular function and eventually improve clinical outcomes at 12-months&#xD;
      in STEMI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:&#xD;
&#xD;
      A multicenter, prospective, randomized, controlled clinical study enroll patients with&#xD;
      ST-segment elevation myocardial infarction (STEMI) intended for PCI with stenting&#xD;
      implantation. Eligible patients are randomly assigned to the immediate stenting group or&#xD;
      delayed stenting group in a 1:1 ratio when residual stenosis &gt;70% and TIMI grade 3 with&#xD;
      angiography guidance.&#xD;
&#xD;
      The index of microcirculation resistance (IMR) is quantitative analysis by an invasive&#xD;
      approach for evaluating post-infarct myocardial microcirculatory perfusion. IMR correlates&#xD;
      with the infarct size of patients with acute myocardial infarction and predicts the&#xD;
      improvement in left ventricular ejection fraction. Studies have shown that acute myocardial&#xD;
      infarction patients with IMR &gt;40 after primary PCI predict adverse long-term clinical&#xD;
      outcomes with higher mortality and heart failure rehospitalization rates.&#xD;
&#xD;
      According to therapeutic strategies and microvascular function detected by IMR, participants&#xD;
      are classified into four groups: immediate stenting with IMR ≥ 40, immediate stenting with&#xD;
      IMR &lt; 40, deferred stenting with IMR ≥ 40 and deferred stenting with IMR &lt; 40. All randomized&#xD;
      patients will be followed by phone call or clinical visit at 12 months.&#xD;
&#xD;
      Patient enrollment and procedure overview:&#xD;
&#xD;
      Patients aged from 18 to 80 with STEMI&lt;12h in whom PCI is planned will be screened.&#xD;
      Thrombectomy and balloon dilatation will be performed at the operator's discretion to restore&#xD;
      an effective antegrade blood flow with TIMI flow grade 3. Patients with residual diameter&#xD;
      stenosis &gt;70% visually and TIMI blood flow grade 3 are eligible for including in the study.&#xD;
      All patients must provide written informed consent and patients will be randomized to&#xD;
      immediate stenting group or deferred stenting group in a 1:1 ratio. All participants in&#xD;
      immediate stenting group will be treated with stent implantation immediately. Those assigned&#xD;
      to the deferred arm will undergo stenting after an interval of 7±2 days. This interval will&#xD;
      be bridged with anti-coagulant and anti-platelet therapy to reduce thrombus burden. All&#xD;
      patients in both groups are required to take dual antiplatelet treatment while the&#xD;
      application of low molecular weight heparin and glycoprotein IIb/IIIa inhibitor are&#xD;
      determined by the operators. All participants are required to perform IMR pre-stenting and&#xD;
      post-stenting to evaluate microcirculation function. All randomized patients will be followed&#xD;
      up to 12 months to evaluate the prevalence of heart failure, all-cause mortality, recurrent&#xD;
      infarction or targeted vessel revascularization.&#xD;
&#xD;
      Study follow-up:&#xD;
&#xD;
      Clinical follow-up:&#xD;
&#xD;
      Participants will be followed by phone calls or clinical visits by study coordinators at 1&#xD;
      month (+/-7 days), 3 months (+/-15 days), 6 months (+/-15 days), 9 months (+/-15 days) and 12&#xD;
      months (+/-30 days) after randomization. Major adverse cardiovascular events (MACEs) will be&#xD;
      recorded throughout the study period until last patient has been followed for 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSMB halted the study due to safety concerns.&#xD;
  </why_stopped>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of heart failure, all-cause death, reinfarction and targeted vessel revascularization within 1 year of STEMI</measure>
    <time_frame>1 year</time_frame>
    <description>MACE including the prevalence of heart failure, all-cause death, reinfarction and targeted vessel revascularization will be collected as the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural myocardial reperfusion reinjury</measure>
    <time_frame>through hospitalization, an average of 7 days</time_frame>
    <description>Prevalence of in-hospital heart failure, all-cause death, re-myocardial infarction or targeted vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success and clinical success</measure>
    <time_frame>postprocedure and through hospitalization, an average of 7 days</time_frame>
    <description>Culprit lesion stenosis&lt;30% in the presence of TIMI 3 grade flow after PCI are regarded as procedural success.&#xD;
Clinical success is determined as procedural success in the absence of in-hospital cardiac death, target vessel myocardial infarction and clinically-driven target lesion revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG ST-segment resolution at 90 minutes after primary PCI</measure>
    <time_frame>90 minutes postprocedure</time_frame>
    <description>We will compare the differences of the ST-segment resolution at 90 minutes among groups after primary PCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peaks of CK, CK-MB, cTnI and area under CK curve</measure>
    <time_frame>through hospitalization, an average of 7 days</time_frame>
    <description>We will compare the peaks of CK, CK-MB, cTnI and area under CK curve while in hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF detected by echocardiographic indices at 7 days after stenting, 1 month and 12 months after discharge</measure>
    <time_frame>7 days, 1 month and 12months</time_frame>
    <description>LVEF will be detected by echocardiographic indices at 7 days after stenting, 1 month and 12 months after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast score index and myocardial blood flow detected by myocardial contrast echocardiography 7 days after stenting and 1 month after discharge</measure>
    <time_frame>7 days and 1 month</time_frame>
    <description>Contrast score index and myocardial blood flow detected by myocardial contrast echocardiography 7 days after stenting and 1 month after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to heart failure</measure>
    <time_frame>1 year</time_frame>
    <description>Prevalence of hospitalization for heart failure will be compared among groups.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">629</enrollment>
  <condition>Microcirculatory Perfusion</condition>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>IMR&lt;40 and defer PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose IMR&lt;40 undergo stent implantation after an interval of 7±2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMR&lt;40 and immediately PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients whose IMR&lt;40 undergo immediately stent implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMR≥40 and defer PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose IMR≥40 undergo stent implantation after an interval of 7±2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMR≥40 and immediately PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients whose IMR≥40 undergo immediately stent implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Deferred or Immediate Stent Implantation</intervention_name>
    <description>IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.</description>
    <arm_group_label>IMR&lt;40 and defer PCI</arm_group_label>
    <arm_group_label>IMR&lt;40 and immediately PCI</arm_group_label>
    <arm_group_label>IMR≥40 and defer PCI</arm_group_label>
    <arm_group_label>IMR≥40 and immediately PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years old ≤ age ≤ 80 years old;&#xD;
&#xD;
          -  STEMI and the onset time &lt;12h;&#xD;
&#xD;
          -  The culprit lesions are de novo lesion;&#xD;
&#xD;
          -  Sign written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients are hemodynamically unstable;&#xD;
&#xD;
          -  Infract-related artery diameter stenosis ≤ 70%;&#xD;
&#xD;
          -  Left main disease;&#xD;
&#xD;
          -  AMI caused by surgery, trauma, gastrointestinal bleeding or PCI and complications;&#xD;
&#xD;
          -  AMI occurs in patients who have been hospitalized for other reasons;&#xD;
&#xD;
          -  The investigator judges that the patient has poor compliance and cannot complete the&#xD;
             study as required;&#xD;
&#xD;
          -  Life expectancy ≤ 12 months;&#xD;
&#xD;
          -  Heart transplant patients;&#xD;
&#xD;
          -  Definite diagnosis of patients with tumors;&#xD;
&#xD;
          -  Participate in other clinical studies (excluding other trials of this project) and&#xD;
             haven't reach the primary endpoints.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Yu</last_name>
    <role>Study Chair</role>
    <affiliation>The Second Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xinshun Gu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lixin Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daqing Longnan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhiyuan Weng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiamusi City Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kai Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mudanjiang cardiovascular hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hui Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shuangyanshan Mining Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shan Gao</last_name>
    <role>Principal Investigator</role>
    <affiliation>the first affiliated hospital of Jiamusi university</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ChunMei Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing An Zhen Hospital, Capital Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing An Zhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second hospital of hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daqing Longnan Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiamusi City Central Hospital</name>
      <address>
        <city>Jiamusi</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jiamusi University</name>
      <address>
        <city>Jiamusi</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mudanjiang Cardiovascular Hospital</name>
      <address>
        <city>Mudanjiang</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shuangyanshan Mining Hospital</name>
      <address>
        <city>Shuangyashan</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yu Bo</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>deferred stent implantation</keyword>
  <keyword>immediate stent implantation</keyword>
  <keyword>microcirculation function</keyword>
  <keyword>ST Elevation Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

